• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

CannaRoyalty Investee Forms Australian Joint Venture

June 28, 2017

 

TORONTO and MELBOURNE, Australia, June 27, 2017 /CNW/ - Resolve Digital Health Inc., a cutting edge Canadian developer of Medical Cannabis delivery systems and devices, has formed a joint venture with LeafCann Group, a leader in the production and development of cannabis medications, clinical research and education, based in Melbourne, Australia. This initiative will grant LeafCann Group a license to register and promote Resolve Digital Health's proprietary Breeze Inhaler system in the Australian market. In addition, LeafCann Group and Resolve Digital Health will conduct clinical trials and pilot studies on the device and formulations in Australia.

 

LeafCann Group will retain an exclusive license to sell and distribute the Breeze device for 3 years, with an option to extend. LeafCann Group will seek import licenses for the Breeze Inhaler and pods for clinical trials and to meet demand from Australia's Special Access Schemes, which allow for limited access to medical devices not yet registered on the Australian Register of Therapeutic Goods.

 

Speaking about this new collaboration, Robert Adelson, CEO of Resolve Digital Health Inc., stated, "Whether in Canada or Australia, our number one priority is patient care.  Resolve Digital Health is pleased to be working with LeafCann to bring relief to Australians who have been prescribed Medical Cannabis in treatment of their ailment."

 

The burgeoning global Medical Cannabis industry is estimated to reach $50 billion by 2025. In support of the growth of the industry in both Australia and Canada, LeafCann and Resolve will collaborate on a series of clinical trials that focus upon symptom relief.  Around the world, Medical Cannabis is prescribed for a plethora of medical conditions, including chronic pain, arthritis and joint disease, migraine headaches, cancer/chemotherapy, fibromyalgia, MS, and many more.

 

"This agreement provides high quality Medical Cannabis products and devices to the Australian market, to meet the needs of patients at end of life and those permitted to access Medical Cannabis products under Australia's Special Access Schemes," said LeafCann Group CEO, Dr. Jaroslav Boublik B.Sc.(Hons) Ph.D. (Med), MRACI, C.Chem. AACNEM, MICRS.

 

About Resolve Digital Health


Resolve Digital Health is positioned to be the leading provider of standardized Medical Cannabis for patients suffering from cancer, arthritis, migraine headaches, chronic pain and other diseases. The company's proprietary technology and cloud-based health information platform found in Resolve's debut product Breeze addresses the numerous issues with currently available methods of cannabis delivery – establishing a standard of care and rigorous medical approach previously missing from the Medical Cannabis industry. With over two years of research and development, the complete product ecosystem will be initially available Fall 2017 in select dispensaries. For more information, visit resolvedigitalhealth.com

 

About LeafCann


LeafCann Group Pty Ltd. is a leading Australian producer and developer of clinical research, product development, education and industry advice to a range of Australian and international partners. LeafCann Group has positioned itself as Australia's preeminent Medical Cannabis think tank. With strong strategic partnerships, a diverse team and significant investment in Medical Cannabis production in Australia, LeafCann Group is well positioned as a global leader. For more information, visit leafcann.com.au

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.